NCT03758287 2022-06-22
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
Sunshine Lake Pharma Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
4 trialsNCT02906163 2016-09-19
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
Phase 1/2 Unknown
NCT00423397 2013-12-19
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00809237 2013-12-10
Hydroxychloroquine and Gefitinib to Treat Lung Cancer
National University Hospital, Singapore
Phase 1/2 Unknown